drugset / Trial / NCT00002066

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

NCT00002066 ↗

Double-blindTreatment

Summary

Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymopentin Peptide — —